SCHEMBL6542484

SCHEMBL6542484

COc1ccc(Cl)cc1C([O])=O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
KCNMA1 Q12791 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 2/20 0.54
POLB P06746 1/20 0.53
TSHR P16473 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
DNMT3A Q9Y6K1 1/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11306685 0.86 LMNA (0.63) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL257135 0.85 LMNA (0.61) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL364764 0.85 ALDH1A1 (0.65) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL30100412 0.85 MRGPRX4 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL48961 0.85 MRGPRX4 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL7210817 0.83 MRGPRX4 (0.62) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL726267 0.83 MAPT (0.60) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL31207306 0.83 MAPT (0.60) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL1095516 0.83 MEN1 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A
SCHEMBL29812845 0.83 MEN1 (0.64) LMNAKCNMA1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1135119-A4 GLUCOSE AND LIPID LOWERING COMPOUNDS ALTEON INC (US) 2004-11-03 EP disclosed
US-6509480-B2 4,7,8 alpha H-eudesma-5(6), 11(13)-dien-8, 12-olide derivatives ALTEON, INC. 2003-01-21 US disclosed
US-20020151581-A1 Glucose and lipid lowering compounds SYNVISTA THERAPEUTICS, INC. 2002-10-17 US disclosed
US-6326396-B1 ACID OR AMIDE COMPOUND ON HYDRONAPHTHALENE COMPOUND ALTEON, INC. 2001-12-04 US disclosed
EP-1135119-A1 GLUCOSE AND LIPID LOWERING COMPOUNDS ALTEON, INC. (US) 2001-09-26 EP disclosed
WO-2000027388-A1 GLUCOSE AND LIPID LOWERING COMPOUNDS ALTEON, INC. (US) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151581-A1 Glucose and lipid lowering compounds HMGCR, APOB, SREBF1 LMNA 1061/4885KCNMA1 3911/4885ALDH1A1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.